Nurix Therapeutics (NRIX) Jefferies 2024 Global Healthcare Conference summary

Pipeline and collaborations

• BTK-targeted protein degrader programs NX-5948 and NX-2127 are in clinical development, with NX-5948 showing promising data in CLL and NHL trials.

• Collaborations with Gilead, Sanofi, and Pfizer are advancing IRAK4 and STAT6 degrader programs, and a new class of Degrader Antibody Conjugates (DACs) is being developed with Pfizer.

• DACs represent a next-generation ADC platform, leveraging highly potent degrader payloads for targeted therapy.

BTK degrader program highlights

• NX-5948 demonstrates high potency against multiple BTK resistance mutations, maintaining efficacy where inhibitors lose effectiveness.

• Clinical trials show a favorable safety profile, with no atrial fibrillation or hypertension observed and increasing response rates as more patients are treated.

• Recent data show a 70% response rate in CLL patients, with durable responses and activity in patients with poor prognosis mutations.

• Case studies highlight efficacy in CNS-involved disease, with resolution of malignant cells in CSF and normalization of blood parameters.

• NX-5948 achieves efficacy at extremely low blood concentrations, indicating a unique PK/PD profile compared to traditional inhibitors.

NX-2127 and dual degrader approach

• NX-2127 targets both BTK and IKZF1/3, providing immunomodulatory effects similar to IMiD drugs.

• Clinical data show dramatic and sustained responses in aggressive lymphomas, including complete responses in diffuse large B-cell and mantle cell lymphoma.

• NX-2127 is positioned for aggressive lymphomas, while NX-5948 is focused on indolent lymphomas and CLL.